Desensitization to protein kinase inhibitors: A systematic kinase

Annals of Allergy, Asthma & Immunology

July 2017 Volume 119, Issue 1, Pages 9-15 MOC/CME Review

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planning Committee Members:
Kelly Chillari, PharmD, (Author)
Sara R. Britnell, PharmD, BCPS, (Author)
Jamie N. Brown, PharmD, BCPS, BCACP, (Author)
Julia M. Hammond, PharmD, BCOP, (Author)
Jonathan A. Bernstein, MD (CME Subcommittee)
Guha Krishnaswamy, MD (CME Subcommittee)
John J. Oppenheimer, MD (CME Subcommittee, Associate Editor)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:
Describe the role of skin testing in protein kinase inhibitor desensitization protocols
Apply principles of evidence-based practice to develop an appropriate patient-specific desensitization tratment plan and select optimal supportive care medications for patients undergoing desensitization

 

Additional information
Disclosure: 

K. Chillari, S.R. Britnell, J.N. Brown and J.M. Hammond have no relevant financial relationships to disclose. Any unapproved/investigative uses of therapeutic agents/devices discussed are appropriately noted. J.A. Bernstein – PI, Consultant, Speaker for AstraZeneca, CSL Behring, Novartis/Genentech, and Shire, he received research grants and fees; Speaker for Baxalta, he received fees; Consultant for Imedics, he received fees; PI and Consultant for Boehringer Ingelheim and GlaxoSmithKline, he received research grants and fees. G. Krishnaswamy – Clinical Research for CSL Behring, he received a research grant; J. Oppenheimer – Consultant for DBV Technologies, GlaxoSmithKline, and Kaleo, he received other financial gains; Clinical research for AstraZeneca, Boehringer Ingelheim, and Novartis, he received research grants. M.H. Grayson – Clinical research for Polyphor, Ltd., he received a research grant. G.D. Marshall – Clinical Research for Stallergens and Sanofi, he received research grants.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC
Course opens: 
07/01/2017
Course expires: 
06/30/2019
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC
Please login or create an account to take this course.